jiliko login
jiliko login
Tackling online violence | Call to include technology-facilitated awareness in schoolsSince Gaza Siege, Israel Has Cracked Down On Its Dissenting Palestinian CitizensFAKRA Coaxial RF Connectors Market 2024: A Decade of Phenomenal Growth Ahead 12-29-2024 06:58 PM CET | Business, Economy, Finances, Banking & Insurance Press release from: Prudent Markets FAKRA Coaxial RF Connectors Market The FAKRA Coaxial RF Connectors Market 2024-2023 report provides a comprehensive analysis of Types (FAKRA PCB Plug Connectors, FAKRA Cable Jack Connectors, FAKRA Cable Plug Connectors), Application (GPS, Infotainment & Television, Safety & Security, In-Vehicle Network, Others), Analysis of Industry Trends, Growth, and Opportunities, R&D landscape, Data security and privacy concerns Risk Analysis, Pipeline Products, Assumptions, Research Timelines, Secondary Research and Primary Research, Key Insights from Industry Experts, Regional Outlook and Forecast, 2024-2032. Major Players of FAKRA Coaxial RF Connectors Market are: Rosenberger, Amphenol, Molex, TE Connectivity, JAE, IMS Connector Systems, Hosiden, SMK, Raydiall Automotive, Yamaichi Electronics, Robert Karst, MITSUMI Group, Pasternack, Electric Connector Technology (ECT), Chant Sincere, Suzhou Recodeal, Wenzhou Yihua Connector, ACES Electronics, Dongguan Tin Wei Electronic Technology, Shenzhen Sihanming Technology Get PDF Sample Report Now! @ https://www.prudentmarkets.com/sample-request/9169813/ FAKRA (Fachkreis Automobil, a german standard) connectors are SMB based automotive-grade connectors that can operate up to 6 GHz. These connectors are embedded within a plastic housing with a locking feature that has an audible clicking noise which lets you know a connection has been made. They are available in 14 different mechanical layouts which are color coded for easy identification and mis-matching prevention. FAKRA connectors meet the mechanical and environmental requirements of the automotive industry. The worldwide automotive industry has standardized on connectors based on the FAKRA and USCAR standards. They can be used in for to make various connections in automotive vehicles, applications include SDARS, Cellular, GPS Navigation, key-less entry and satellite radio. This report provides a deep insight into the global FAKRA Coaxial RF Connectors market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc. The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global FAKRA Coaxial RF Connectors Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market. Segmentation of FAKRA Coaxial RF Connectors Market- By Type FAKRA PCB Plug Connectors, FAKRA Cable Jack Connectors, FAKRA Cable Plug Connectors By Application GPS, Infotainment & Television, Safety & Security, In-Vehicle Network, Others Geographic Segmentation -North America (USA, Canada, Mexico) -Europe (Germany, UK, France, Russia, Italy, Rest of Europe) -Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific) -South America (Brazil, Argentina, Columbia, Rest of South America) -The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA) Prudent Markets provides attractive discounts that fit your needs. Customization of the reports as per your requirement is also offered. Get in touch with our sales team, who will guarantee you a report that suits your needs. Speak To Our Analyst For A Discussion On The Above Findings, And Ask For A Discount On The Report @ https://www.prudentmarkets.com/discount-request/9169813/ Key Benefits of the Report: This study presents the analytical depiction of the FAKRA Coaxial RF Connectors Industry along with the current trends and future estimations to determine the imminent investment pockets. The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the FAKRA Coaxial RF Connectors Market share. The current market is quantitatively analyzed from to highlight the Global Gardening Pots Market growth scenario. Porter's five forces analysis illustrates the potency of buyers & suppliers in the market. The report provides a detailed FAKRA Coaxial RF Connectors Market analysis based on competitive intensity and how the competition will take shape in coming years. Key poles of the TOC: Chapter 1 FAKRA Coaxial RF Connectors Market Business Overview Chapter 2 Major Breakdown by Type Chapter 3 Major Application Wise Breakdown (Revenue & Volume) Chapter 4 Manufacture Market Breakdown Chapter 5 Sales & Estimates Market Study Chapter 6 Key Manufacturers Production and Sales Market Comparison Breakdown Chapter 8 Manufacturers, Deals and Closings Market Evaluation & Aggressiveness Chapter 9 Key Companies Breakdown by Overall Market Size & Revenue by Type Chapter 11 Business / Industry Chain (Value & Supply Chain Analysis) Chapter 12 Conclusions & Appendix The report covers the competitive analysis of the market. As the demand is driven by a buyer's paying capacity and the rate of item development, the report shows the important regions that will direct growth. This section exclusively shares insight into the budget reports of big-league members of the market helping key players and new entrants understand the potential of investments in the Global FAKRA Coaxial RF Connectors Market. It can be better employed by both traditional and new players in the industry for complete know-how of the market. For In-Depth Competitive Analysis - Purchase this Report now at a Complete Table of Contents (Single User License) @ https://www.prudentmarkets.com/checkout/?id=9169813&license_type=su Free Customization on the basis of client requirements on Immediate purchase: 1- Free country-level breakdown of any 5 countries of your interest. 2- Competitive breakdown of segment revenue by market players. Customization of the Report: This report can be customized to meet the client's requirements. Please connect with our sales team (sales@prudentmarkets.com), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +91 83560 50278 || USA/Canada(Toll Free): 1800-601-6071 to share your research requirements. In conclusion, the FAKRA Coaxial RF Connectors Market report is a genuine source for accessing the research data which is projected to exponentially grow your business. The report provides information such as economic scenarios, benefits, limits, trends, market growth rates, and figures. SWOT analysis and PESTLE analysis is also incorporated in the report. Contact Us: Allan Carter Andheri, Maharashtra, 400102 USA/Canada(Toll Free): 1800-601-6071 Direct Line: +91 83560 50278 Mail: sales@prudentmarkets.com Web: www.prudentmarkets.com About Us: We are leaders in market analytics, business research, and consulting services for Fortune 500 companies, start-ups, financial & government institutions. Since we understand the criticality of data and insights, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available. To be at our client's disposal whenever they need help on market research and consulting services. We also aim to be their business partners when it comes to making critical business decisions around new market entry, M&A, competitive Intelligence and strategy. This release was published on openPR.
Best Bets for NCAA Basketball Picks Against the Spread for Monday, November 25Pressure is mounting on Australia's largest bank to scrap account changes that charge some customers to access their own cash. or signup to continue reading Blasted as greedy and out of touch, Commonwealth Bank will shift all customers with a "Complete Access" account to a "Smart Access" account, which includes an "assisted withdrawal fee". The $3 fee hits customers when they take cash out from bank branches, post offices or over the phone, but it does not include withdrawals from ATMs. Age, service and disability pensioners, customers aged under 18 and people with disabilities that require them to use branches will have the fee waived. But that has not stopped a pile-on from prominent politicians, who have urged the bank to reconsider the decision. "People understand there's some charges relating to banking transactions, but this seems pretty extraordinary to have a charge of this size for a simple transaction of going into a bank and withdrawing your own money," Finance Minister Katy Gallagher told Nine's Today program on Wednesday. Fellow Labor minister Clare O'Neil said the move was a "kick in the guts". "Everyone's had a bit of a tough year on the cost-of-living front ... come on guys, it's Christmas, we don't need this right now," she told Seven's Sunrise. The bank said its fees on the Smart Access account, its main transaction account, had not changed and it continued to offer withdrawal fee waivers for eligible customers. But Liberal senator Jane Hume said customers would vote with their feet and close their accounts - including herself. "I have a Commonwealth Bank account I've had since I was at university, I will be shutting it because of this decision," she said. "I don't know whether it's a Complete Access account or not (but) it's a bad decision and I will be shutting my account." Independent MP Monique Ryan said the move showed cash was under threat in Australia. The government recently announced proposed mandate for businesses like supermarkets, pharmacies and petrol stations that sell essential items to accept cash payments. About 94 per cent of businesses accept cash, but this is down from 99 per cent before the COVID-19 pandemic. DAILY Today's top stories curated by our news team. WEEKDAYS Grab a quick bite of today's latest news from around the region and the nation. WEEKLY The latest news, results & expert analysis. WEEKDAYS Catch up on the news of the day and unwind with great reading for your evening. WEEKLY Get the editor's insights: what's happening & why it matters. WEEKLY Love footy? We've got all the action covered. WEEKLY Every Saturday and Tuesday, explore destinations deals, tips & travel writing to transport you around the globe. WEEKLY Going out or staying in? Find out what's on. WEEKDAYS Sharp. Close to the ground. Digging deep. Your weekday morning newsletter on national affairs, politics and more. TWICE WEEKLY Your essential national news digest: all the big issues on Wednesday and great reading every Saturday. WEEKLY Get news, reviews and expert insights every Thursday from CarExpert, ACM's exclusive motoring partner. TWICE WEEKLY Get real, Australia! Let the ACM network's editors and journalists bring you news and views from all over. AS IT HAPPENS Be the first to know when news breaks. DAILY Your digital replica of Today's Paper. Ready to read from 5am! DAILY Test your skills with interactive crosswords, sudoku & trivia. Fresh daily! Advertisement Advertisement
Eagles-Ravens Week 13 injury report, with analysis
Natixis Advisors LLC cut its stake in shares of United Therapeutics Co. ( NASDAQ:UTHR – Free Report ) by 4.2% in the 3rd quarter, Holdings Channel.com reports. The fund owned 17,011 shares of the biotechnology company’s stock after selling 739 shares during the period. Natixis Advisors LLC’s holdings in United Therapeutics were worth $6,096,000 as of its most recent SEC filing. Several other large investors have also recently modified their holdings of the stock. UniSuper Management Pty Ltd raised its holdings in United Therapeutics by 133.3% in the first quarter. UniSuper Management Pty Ltd now owns 700 shares of the biotechnology company’s stock worth $161,000 after buying an additional 400 shares during the last quarter. Canada Pension Plan Investment Board increased its position in shares of United Therapeutics by 567.2% during the first quarter. Canada Pension Plan Investment Board now owns 180,800 shares of the biotechnology company’s stock valued at $41,533,000 after acquiring an additional 153,700 shares in the last quarter. Bayesian Capital Management LP bought a new position in United Therapeutics in the 1st quarter valued at approximately $772,000. B. Riley Wealth Advisors Inc. bought a new position in United Therapeutics in the 1st quarter valued at approximately $219,000. Finally, California State Teachers Retirement System increased its holdings in shares of United Therapeutics by 2.1% in the 1st quarter. California State Teachers Retirement System now owns 74,773 shares of the biotechnology company’s stock worth $17,177,000 after purchasing an additional 1,525 shares in the last quarter. Hedge funds and other institutional investors own 94.08% of the company’s stock. Analyst Upgrades and Downgrades Several research firms recently commented on UTHR. Bank of America dropped their price objective on United Therapeutics from $303.00 to $280.00 and set an “underperform” rating on the stock in a research report on Thursday, August 1st. Wells Fargo & Company lifted their price target on shares of United Therapeutics from $350.00 to $380.00 and gave the stock an “overweight” rating in a research note on Tuesday, August 20th. Argus raised their target price on shares of United Therapeutics from $360.00 to $400.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. TD Cowen lifted their target price on shares of United Therapeutics from $350.00 to $400.00 and gave the stock a “buy” rating in a research report on Monday, October 21st. Finally, StockNews.com raised United Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Thursday, October 17th. One analyst has rated the stock with a sell rating, two have assigned a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $370.86. United Therapeutics Stock Up 1.5 % NASDAQ UTHR opened at $372.89 on Friday. United Therapeutics Co. has a 52 week low of $208.62 and a 52 week high of $417.82. The company has a market capitalization of $16.65 billion, a P/E ratio of 16.38, a price-to-earnings-growth ratio of 1.05 and a beta of 0.56. The stock’s 50-day moving average price is $365.06 and its 200-day moving average price is $331.37. United Therapeutics ( NASDAQ:UTHR – Get Free Report ) last issued its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share for the quarter, beating the consensus estimate of $6.16 by $0.23. The business had revenue of $748.90 million for the quarter, compared to the consensus estimate of $722.62 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The company’s revenue for the quarter was up 22.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned $5.38 earnings per share. Research analysts anticipate that United Therapeutics Co. will post 25.1 EPS for the current year. Insider Buying and Selling In other United Therapeutics news, CFO James Edgemond sold 7,802 shares of the company’s stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $345.41, for a total value of $2,694,888.82. Following the completion of the transaction, the chief financial officer now directly owns 3,210 shares in the company, valued at $1,108,766.10. This represents a 70.85 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website . Also, CEO Martine A. Rothblatt sold 269 shares of United Therapeutics stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $348.41, for a total transaction of $93,722.29. Following the sale, the chief executive officer now owns 130 shares in the company, valued at approximately $45,293.30. The trade was a 67.42 % decrease in their position. The disclosure for this sale can be found here . In the last quarter, insiders sold 117,496 shares of company stock valued at $43,765,042. Company insiders own 11.90% of the company’s stock. United Therapeutics Profile ( Free Report ) United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. Recommended Stories Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Co. ( NASDAQ:UTHR – Free Report ). Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter .
Grad assistant coach suits up to fill QB void, sets Southern Illinois record with 7 TD passesOne of the hardest questions to answer is a deceptively simple one: who are you? But this is precisely the question that “reminiscence” or “life review” therapies, which draw on autobiographical memory, looks to answer. It’s normal to think about our past or to relive memories in conversations with friends, but it is rare to do so in a considered, intentional way. In 2022, Jane Fonda spoke about conducting a life review after turning 60, telling Glamour , “it totally changed the way I thought about myself and about how I wanted to live the last third of my life”. But whether you’re 60 or 16, looking backwards can be a useful exercise in building purpose and meaning into your present and future. Credit: iStock What is reminiscence therapy? Reminiscence therapy is an umbrella term that encompasses a range of therapeutic approaches. Loading David Hallford, a senior lecturer at Deakin University’s School of Psychology, says most therapy, “either implicitly or explicitly draws on memory”. “But reminiscence therapy is particularly focused on retrieving, reflecting on and reframing experiences into our understanding of ourselves.” Broadly speaking, he says reminiscence focuses on specific themes, like relationships, loss or challenges faced. Life review, on the other hand, is about a more systematic approach to reflecting on experiences across a whole lifetime. And reminiscence is about more than just mapping the big beats in our lives. Sunil Bhar, a professor of psychology at Swinburne University of Technology, says: “It’s not simply about documenting things, like where someone lived or who they married, where they end up with what is essentially a resume of their life. “We’ve discovered that what’s therapeutic about going back over someone’s life is not what they did, but who they are .” Reminiscence, he says, can help people answer the tricky question of “who are you?” “The most common answer to [this question] is, ‘I am a student’, ‘I am a daughter’, ‘I’m a son’; you talk about yourself in terms of the roles that you played in your life,” he says. “So reminiscence is a way of getting to the values that have been driving those roles and those life decisions.” What are its benefits? Research on reminiscence therapy has focused mostly on its benefits for older people, where it’s been shown to improve things like depression and life satisfaction . For people with dementia, reminiscence therapy can help create a sense of agency and improve mental health and cognition. Research has also found it can lessen the effects of anxiety and depression and that it can improve quality of life for cancer patients . However, an emerging body of research shows that reflecting on our lives can be beneficial at any age. Hallford’s research focuses on the benefits of life review , particularly for young adults. He thinks a lack of research is partly for cultural reasons, where there is the “preconception of sitting around and thinking about the good old days as a task of older adulthood, when we are not necessarily completing as many big life tasks like getting our careers started or having kids”. But the benefits of reminiscence therapy in older adults are much the same for younger ones. Research has shown reminiscence therapy to improve levels of self-esteem , confidence, optimism and life satisfaction . One small study led by Hallford this year found guided recall and interpretation of autobiographical memories helped improve young adults’ self-perception and views of others. Used in clinical settings, it has also been shown to reduce depression and anxiety, where it’s often part of a program involving cognitive behaviour therapy. Three great questions to ask A question professor Sunil Bhar likes to ask in his practice is, tell me the story of your name . This simple question can be a gentle launching pad into the story of someone’s life – from their cultural heritage to their family history. Another good exercise, professor David Hallford says, is to talk about a time you overcame a challenge . “You’re not only disclosing and building a bond with someone else, but you’re also reinforcing and activating in your own mind this idea of what that means about yourself,” he says. Other prompts, Bhar suggests, can revolve around things that have been special to them, such as, tell me about a person in your life who has had an enduring effect on you? How it works Typically, reminiscence therapy is conducted by a psychologist, either in a group setting or one on one. To explore this kind of therapy, you can chat to your GP, counsellor or psychologist. Loading But you can still reap the benefits by reflecting on the past in a less structured way with friends or family. “There is a sense in the literature that maybe what is therapeutic about reminiscence therapy isn’t the outpouring of memories, but really it’s having someone listen,” says Bhar. “It brings the idea that what we’re really after is a human connection, and reminiscence is simply a way of eliciting that.” Hallford says journaling or voice recordings can help with this. It’s also common to use physical objects or music to prompt memories. Bhar says photographs can be a good starting point for talking about the past. So whether you’re spending the break alone or with friends or family, consider going through an old album, or talking about what matters to you most. It might help crystallise who you are. Make the most of your health, relationships, fitness and nutrition with our Live Well newsletter . Get it in your inbox every Monday . Save Log in , register or subscribe to save articles for later. License this article Wellbeing Psychology Ageing Dementia Mental health For subscribers Lauren Ironmonger – Lauren is a lifestyle writer at the Sydney Morning Herald. Connect via email . Most Viewed in Lifestyle Loading
Soitec SA (OTCMKTS:SLOIF) Short Interest UpdateFive women among seven Bangladeshi nationals deported
Shares of iShares iBonds Mar 2023 Term Corporate ETF ( NYSEARCA:IBDD – Get Free Report ) were up 0.1% on Friday . The company traded as high as $26.59 and last traded at $26.59. Approximately 4,200 shares changed hands during trading, a decline of 86% from the average daily volume of 30,028 shares. The stock had previously closed at $26.57. iShares iBonds Mar 2023 Term Corporate ETF Stock Performance The business has a fifty day moving average of $26.59 and a two-hundred day moving average of $26.59. iShares iBonds Mar 2023 Term Corporate ETF Company Profile ( Get Free Report ) The iShares iBonds Mar 2023 Term Corporate ETF (IBDD) is an exchange-traded fund that is based on the Bloomberg 2023 Maturity Corporate index. The fund tracks a Bloomberg index composed of USD denominated, investment-grade corporate bonds maturing after March 31, 2022 and before April 1, 2023. IBDD was launched on Jul 9, 2013 and is managed by BlackRock. Recommended Stories Receive News & Ratings for iShares iBonds Mar 2023 Term Corporate ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares iBonds Mar 2023 Term Corporate ETF and related companies with MarketBeat.com's FREE daily email newsletter .Mocked on TN streets for learning Hindi, says FM Nirmala Sitharaman
Trump’s tariffs in his first term did little to alter the economy, but this time could be different
Kinziger's FTs lift Illinois State to consi win over UAB at Paradise Jam
CEDAR FALLS, IOWA — The Saluki men's basketball team held a nine-point lead over Northern Iowa with just over five minutes in the first half, but the Panthers would close out the opening half on a 13-0 run en route to a 78-67 win Sunday afternoon at the McLeod Center. "They were more physical than we were, really on both ends," head coach Scott Nagy said following the loss. "We got off to a better start in this game, but when things got tight, we just couldn't run the offense. They weren't going to let us run what we wanted, and they just played more physical than us on the offensive end." Javascript is required for you to be able to read premium content. Please enable it in your browser settings.FACT FOCUS: Vermont ruling does not say schools can vaccinate children without parental consent
